TXMD
$2.24+0.01 (+0.45%)
Market ClosedAs of Mar 20, 8:00 PM UTC
TherapeuticsMD, Inc.
Historical Price
Price (Line)
50-Day SMA
200-Day SMA
Synthesizing Whystock Narrative...
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Calculated using a trailing P/E relative model adjusted by sector ROE and historical growth.
Current Price$2.24
Potential Downside
69.7%
Whystock Fair Value$0.68
Price
UndervaluedFair ValueOvervalued
Fundamentals
TherapeuticsMD, Inc. operates as a pharmaceutical royalty company in the United States. It has a license agreement with Mayne Pharma to commercialize the IMVEXXY, BIJUVA, and ANNOVERA prescription prenatal vitamin products sold under the BocaGreenMD ...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$25.93M
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
224.00
Beta
Defensive asset. Lower volatility than the S&P 500.
0.54
Div Yield
Low to zero yield. Return is entirely dependent on price appreciation.
0.00%
ROIC
Elite ROE. Management converts capital into profit efficiently.
248.90%
Quick Ratio
Pristine liquidity. Sufficient cash to cover all near-term obligations.
2.93
Recent News
TherapeuticsMD: Q3 Earnings Snapshot
BOCA RATON, Fla. AP) — TherapeuticsMD Inc. TXMD) on Wednesday reported earnings of $152,000 in its third quarter.
TherapeuticsMD: Q2 Earnings Snapshot
BOCA RATON, Fla. AP) — TherapeuticsMD Inc. TXMD) on Tuesday reported net income of $551,000 in its second quarter.
TherapeuticsMD: Q1 Earnings Snapshot
BOCA RATON, Fla. AP) — TherapeuticsMD Inc. TXMD) on Tuesday reported a loss of $653,000 in its first quarter.
TherapeuticsMD Full Year 2024 Earnings: US$0.20 loss per share (vs US$0.74 loss in FY 2023)
TherapeuticsMD ( NASDAQ:TXMD ) Full Year 2024 Results Key Financial Results Net loss: US$2.31m (loss narrowed by 70...